Sage Therapeutics Inc
SAGE
Get informed when a big investor buys or sells
+ FollowMarket Cap$544.94M
Close$
$-8.39
196.7% downside
Current Fair Value
196.7% downsideOvervalued by 196.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $544.94 Million |
|---|---|
| Enterprise Value | $489.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.59 |
| Beta | 0.3 |
| Outstanding Shares | 62,610,598 |
Return
| Return on Equity | -81.68% |
|---|---|
| Return on Assets | -71.22% |
| Return on Invested Capital | -80.12% |
Valuation & Multiples
| P/E Ratio | -2.62 |
|---|---|
| PEG | 5.06 |
| Price to Sales | 8.68 |
| Price to Book Ratio | 1.74 |
| Enterprise Value to Revenue | 6.95 |
| Enterprise Value to EBIT | -1.62 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5850▼ 112.80% |
|---|---|
| Total Calls | 752,500▲ 313.69% |
| Total Puts | 440,200▲ 41.27% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 78.06%▼ 5.60% |
|---|---|
| Total Invested | $445.74M▲ 8.32% |
| Investors Holding | 204▼ 1.00% |
ESG Score
No data
About Sage Therapeutics Inc
CEO: Jeffrey Jonas